The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Prospective cohort study of impulse control disorders in Parkinson's disease
Open accessAbstract
Impulse control disorders (ICDs) are potentially serious side effects of dopamine agonist therapy in Parkinson's disease (PD), but prospective data are lacking about their incidence, time course, and risk factors. This work was a 4‐year, prospective cohort study of outpatients with PD and no previous ICDs (N = 164). All subjects treated with a dopamine agonist during the study were followed longitudinally for new‐onset ICDs. Baseline characteristics were compared in groups with (ICD+) and without (ICD−) subsequent ICDs. Forty‐six subjects were treated with a dopamine agonist, including 25 who were newly treated and 21 who received ongoing dopamine agonist therapy. Of these 46 subjects, 18 (39.1%) developed new‐onset ICDs. The timing of ICD onset varied from 3.0 to 114.0 months (median, 23.0) after initiation of dopamine agonist therapy. Baseline demographic characteristics were similar in ICD+ and ICD− groups. At baseline, ICD+ subjects had a greater prevalence of motor complications (61.1% versus 25.0%; P = 0.01) than ICD− subjects, despite comparable total dopaminergic medication usage in both groups (median, 150.0 versus 150.0 levodopa equivalents; P = 0.61). Compared with ICD− subjects, ICD+ subjects had a greater baseline prevalence of caffeine use (100% versus 66.7%; P = 0.007) and higher lifetime prevalence of cigarette smoking (44.4% versus 14.3%; P = 0.04). Peak dopamine agonist doses were higher in ICD+ than ICD− subjects (median 300.0 versus 165.0 L‐dopa equivalents; P = 0.03), but cumulative dopamine agonist exposure was similar in both groups. In summary, the timing of new‐onset ICDs in PD is highly variable. Risk factors include cigarette smoking, caffeine use, motor complications, and higher peak dopamine agonist dosage. © 2013 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Cools, R. (2001) · Cerebral Cortex · doi:10.1093/cercor/11.12.1136 · Cited by 906
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662 · cited 2×
“Moreover, although the primary treatment for ICDs is to taper or discontinue DAA therapy, not all patients are able to tolerate this because of motor worsening or because of dopamine agonist withdrawal syndrome (DAWS), a severe nonmotor drug withdrawal syndrome that mimics that of cocaine and other psychostimulants.(1…”
BackgroundMethodThe neurocircuitry of impaired insight in drug addiction
Goldstein, R. Z., Craig, A. D. (., Bechara, A., Garavan, H., Childress, A. R., Paulus, M. P., & Volkow, N. D. (2009) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2009.06.004 · Cited by 641
Cited by
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Voon, V., Napier, T. C., Frank, M. J., Sgambato-Faure, V., Grace, A. A., Rodriguez-Oroz, M., Obeso, J., Bezard, E., & Fernagut, P.-O. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30004-2 · Cited by 359
Clinical spectrum of impulse control disorders in Parkinson’s disease
Weintraub, D., David, A. S., Evans, A. H., Grant, J. E., & Stacy, M. (2015) · Movement Disorders · doi:10.1002/mds.26016 · Cited by 311
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub, D., Simuni, T., Caspell‐Garcia, C., Coffey, C., Lasch, S., Siderowf, A., Aarsland, D., Barone, P., Burn, D., Chahine, L. M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26170 · Cited by 305
Metadata
- Authors
- Bastiaens, J., Dorfman, B. J., Christos, P. J., & Nirenberg, M. J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2013-01-02
- Volume
- 28
- Issue
- 3
- Pages
- 327-333
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1910174704
- Cited by
- 168
- References
- 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective cohort study of impulse control disorders in Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.25291
- The paper
- Bastiaens, J., Dorfman, B. J., Christos, P. J., & Nirenberg, M. J. (2013). Prospective cohort study of impulse control disorders in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.25291
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.